Repeated polysomnography and multiple sleep latency test in narcolepsy type 1 and other hypersomnolence disorders

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 785 KB, PDF-dokument

Background
The diagnosis of narcolepsy is based on clinical information, combined with polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT). PSG and the MSLT are moderately reliable at diagnosing narcolepsy type 1 (NT1) but unreliable for diagnosing narcolepsy type 2 (NT2). This is a problem, especially given the increased risk of a false-positive MSLT in the context of circadian misalignment or sleep deprivation, both of which commonly occur in the general population.

Aim
We aimed to clarify the accuracy of PSG/MSLT testing in diagnosing NT1 versus controls without sleep disorders. Repeatability and reliability of PSG/MSLT testing and temporal changes in clinical findings of patients with NT1 versus patients with hypersomnolence with normal hypocretin-1 were compared.

Method
84 patients with NT1 and 100 patients with non-NT1-hypersomnolence disorders, all with congruent cerebrospinal fluid hypocretin-1 (CSF-hcrt-1) levels, were included. Twenty-five of the 84 NT1 patients and all the hypersomnolence disorder patients underwent a follow-up evaluation consisting of clinical assessment, PSG, and a modified MSLT. An additional 68 controls with no sleep disorders were assessed at baseline.

Conclusion
Confirming results from previous studies, we found that PSG and our modified MSLT accurately and reliably diagnosed hypocretin-deficient NT1 (accuracy = 0.88, reliability = 0.80). Patients with NT1 had stable clinical and electrophysiological presentations over time that suggested a stable phenotype. In contrast, the PSG/MSLT results of patients with hypersomnolence, and normal CSF-hcrt-1 had poor reliability (0.32) and low repeatability.
OriginalsprogEngelsk
TidsskriftSleep Medicine
Vol/bind110
Sider (fra-til)91-98
Antal sider8
ISSN1389-9457
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Dr. Mignot reports non-financial support from Idorsia Pharmaceuticals Ltd, and personal fees from Jazz Pharmaceuticals, Alairion, ALPCO, INEXIA, Merck, Orexia, Dreem, and Sunovion during the course of the study. Dr. Kornum is a founder of Ceremedy and reports personal fees from Orexia Therapeutics and Novartis. Dr. Torstensen, Dr. Barloese, Dr. Jennum, and Dr. Wanscher have nothing to disclose.

Publisher Copyright:
© 2023 The Authors

ID: 362738260